Source: Fox News
Summary
The FDA has approved Foundayo (orforglipron), a once-daily weight-loss pill developed by Lilly. Clinical trial participants lost an average of 27.3 pounds (12.4%) on the highest dose. The pill can be taken at any time of day without food or water restrictions. It is intended for adults who are overweight or obese and have weight-related medical problems. Foundayo is also being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, and other conditions.
Our Reading
The advice sounds familiar.
Foundayo is the latest addition to the GLP-1 medication family, which has been expanding rapidly in recent years. The treatment’s effectiveness is enhanced when combined with a reduced-calorie diet and increased physical activity. However, the manufacturer warns of potential side effects, including gastrointestinal issues and the risk of thyroid tumors. As with other GLP-1s, the medication’s long-term effects are still being studied. The FDA approval marks Lilly’s second obesity medicine, following Zepbound (tirzepatide). The treatment is expected to be available to patients starting April 6.
The cycle of new weight-loss medications with varying degrees of effectiveness and potential side effects continues.
Author: Evan Null
